Synpromics expansion to support growing gene control business

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Jirsak
Image: iStock/Jirsak

Related tags: Dna, Gene

Moving to a larger facility will help Scottish firm Synpromics Ltd increase its gene control and cell line services presence, the firm says.

The gene control and synthetic promoter development firm has moved into a new facility at the Roslin Innovation Centre, about 10km south of Edinburgh, UK adding over 5,000 sq ft of lab and office space.

The expansion fits with the firm’s growth strategy which saw revenues reach over £1.2m ($1.6m) in 2016, and according to Synpromics founder and CSO Michael Robert, further growth is expected this year.

Synpromics is committed to be the global leader in gene control,” ​he told Biopharma-Reporter. “This move into a world-class facility enables us to realise that goal, giving us access to an excellent infrastructure and cutting-edge research being undertaken at the Roslin Institute.”

He added the firm is looking to grow in size by an extra 25% over the coming year, and the move will provide the room for new staff and equipment.

“It gives us the space that we need for the expanding team, in particular providing the creative environment that allows our scientists to flourish, meaning we can more effectively build on our PromPT platform and meet the growing demand for our technology.”

Synpromics’ PromPT platform is a bioinformatics database for the design, build and screening of synthetic promoters. These promoters allow for precise control of gene function, impacting gene therapy, cell therapy and gene editing.

In the past year, the firm has inked a number of agreements, including separate deals with GE Healthcare​ and Sartorius​ to increase stability and yield, and reduce the lead time, of CHO cell lines used in bioprocessing.

It also received a £5.2m boost in April​ in the form of funding from UK-based companies Calculus Capital, the Scottish Investment Bank, the investment branch of Scottish Enterprise, and private shareholders.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars